12 results about "Cholecystokinin" patented technology

The present invention relates to a cholecystokinin (CCK) antagonist for use in the prevention and / or treatment of a vestibular disease or disorder selected from motion sickness, Meniere's disease, vestibular migraine, disembarkment sickness, labyrinthitis, vestibular neuronitis, benign paroxysmal positional vertigo, labyrinthine infarction and nausea.

The invention discloses a peptidomimetic compound as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The peptidomimetic compound is shown as a formula I in the specification. The compound can act on the nerve center, has anti-epilepsy and anti-depression effects, can also act on the gastrointestinal tract, inhibits gastric acid secretion or tumor cell growth, is a novel cholecystokinin type 2 receptor antagonist, and has a great application prospect.

The present invention relates to an active oligopeptide RYIVPL, its preparation method and application. The active oligopeptide is RYIVPL, and its amino acid sequence is: Arg-Tyr-Ile-Val-Pro-Leu, which has the remarkable function of stimulating intestinal endocrine cells to secrete cholecystokinin (CCK). Compared with the prior art, the oligopeptide of the present invention can be artificially synthesized by a chemical solid-phase synthesis method, or can be obtained by enzymatic hydrolysis of wheat protein followed by separation and purification. The oligopeptide of the present invention has the characteristics of being safe, non-toxic and having no side effects, not being easily enzymolyzed by gastrointestinal digestive enzymes, and being easily absorbed, and is suitable as a functional component for developing drugs with the functions of delaying gastric emptying, promoting satiety and weight loss, and has great application value and broad prospects in the fields of medicine and the like.

Compositions comprising satiety peptides (e.g., PYY, PYY(3-36), GLP-1, oxyntomodulin, and cholecystokinin) and DPP-IV inhibitors and methods of treating metabolic diseases with such compositions are provided.

The present application relates to the technical field of bioactive peptides, and in particular to an oat oligopeptide, preparation thereof and application thereof in preparing a product for regulating the expression of brain appetite suppressor factor. The oat oligopeptide can effectively stimulate the release of cholecystokinin (CCK) from intestinal endocrine cells, and stimulate the central nervous system through the vagus nerve pathway, thereby promoting the expression of the appetite suppressor factor pro-opiomelanocortin (POMC) in the hypothalamus. Compared with the prior art, the oat oligopeptide has the advantages of stable structure, high safety, simple preparation process (conventional enzymatic hydrolysis and chromatographic purification can achieve the preparation), easy scale production and the like. The oat oligopeptide is suitable for being used as a functional ingredient or a drug precursor to develop a related health product with the functions of regulating appetite and promoting satiety, and has a wide application prospect in the field of preparing functional products (food, medicine and the like).

The invention provides a social disorder animal model construction method based on a basal lateral amygdaloid nucleus-screen nucleus neural circuit and application thereof, and belongs to the technical field of animal model construction. The method comprises the following steps: injecting a viral vector carrying a photosensitive protein gene or a photosuppressive protein gene into amygdaloid nucleus on the outer side of an animal basal to express neurons of cholecystokinin or neurons of CaMKII alpha; embedding an optical fiber above the screen-shaped core; first light stimulation is applied through an optical fiber to activate nerve projection from amygdaloid nucleus on the outer side of the substrate to the screen nucleus, and a social disorder animal model is obtained; or applying a second photostimulus to inhibit the projection, resulting in a social disorder relief animal model. According to the invention, specific photogenetic regulation and control of the BLACCK +-CLA neural circuit is realized for the first time, social behaviors can be accurately regulated and controlled without interfering with movement and anxiety levels, and a reliable experimental tool is provided for mechanism research and drug screening of social obstacles.

The invention provides a preparation method and application of a protein nanocage loaded with tuna peptide. The preparation method specifically comprises the following steps: constructing and modifying an iron protein nanocage, and extracting, screening and embedding tuna active peptide. The tuna active peptides are embedded in ferulic acid modified ferritin nanocages, and are delivered into intestinal tracts in a targeted manner to react with anorexia hormone receptors, so that the generation of anorexia hormones such as cholecystokinin, glucagon-like peptide 1 and PYY is regulated, the appetite after normal diet is controlled, and the satiety of the body is enhanced; the effects of reducing food intake and reducing body weight are achieved, so that the composition plays a role in regulating obesity. Ferulic acid is utilized to modify the ferritin nanocage, carboxyl and phenolic hydroxyl groups in the ferritin nanocage react with amino terminals on the outer surface of the ferritin nanocage, so that the ferritin nanocage is endowed with a gastric juice environment resisting function, and the ferritin nanocage can stably exist in the stomach of an organism without being decomposed, so that the ferritin nanocage is decomposed in intestinal tracts and plays a role in precise targeting; and a foundation is laid for anti-obesity research.

The present invention relates to compounds and methods for the targeted delivery of diagnostic / therapeutic radionuclides to cancer tissue. In particular, the present invention relates to the targeted delivery of diagnostic / therapeutic radionuclides to cholecystokinin-2 receptor positive cancers and methods for the diagnosis and treatment of cancer.

The present invention relates to a cholecystokinin (CCK) antagonist for use in the prevention and / or treatment of a vestibular disease or disorder selected from motion sickness, Meniere's disease, vestibular migraine, disembarkment sickness, labyrinthitis, vestibular neuronitis, benign paroxysmal positional vertigo, and labyrinthine infarction. It also relates to a drug combination comprising a CCK antagonist and a GLP1 receptor agonist, to compositions comprising this combination, and to a CCK antagonist for use in the treatment and / or prevention of adverse side effects associated to a GLP1 receptor agonist, in a subject undergoing therapy with a GLP1 receptor agonist.

The invention provides application of carvacrol in preparation of a feed additive for regulating digestive system disorder of piglets, and belongs to the technical field of animal breeding. The invention discloses application of carvacrol in preparation of a feed additive and / or feed for regulating digestive system disorder of piglets. Experiments prove that the carvacrol effectively relieves the influence of weaning stress on a piglet digestive system, enhances the activity of intestinal digestive enzymes, improves the expression of nutrient transporters, regulates the digestive system, and improves cholecystokinin-mediated ingestion and digestion behaviors of piglets.

The present invention provides a preparation method and application of a protein nanocage loaded with tuna peptides, specifically including the construction and modification of ferritin nanocages, and the extraction, screening, and embedding of tuna active peptides. The tuna active peptides are encapsulated in ferritin nanocages modified with ferulic acid and delivered to the intestines in a targeted manner. They interact with anorexigenic hormone receptors, regulate the production of anorexigenic hormones such as cholecystokinin, glucagon-like peptide 1, and PYY, control appetite after a normal diet, and enhance the body's sense of fullness, thereby reducing food intake and weight loss, thereby playing a role in regulating obesity. In the present invention, ferritin nanocages are modified with ferulic acid. The carboxyl and phenolic hydroxyl groups in the ferulic acid interact with the amino end of the outer surface of the ferritin nanocage, giving the ferritin nanocages the function of being resistant to gastric juice environment. They can exist stably in the stomach of the body without being decomposed, thereby being decomposed in the intestines and exerting their precise targeted effects, laying the foundation for anti-obesity research.

The present invention co-expresses CCK and SS for the first time, constructs pCold-pCCK-SS by selecting a cold shock vector pCold GST DNA, and prepares Transetta (DE3)-pCold-pCCK-SS recombinant bacteria, which can efficiently express pCCK-SS recombinant protein. The protein is used for laying hen immunization to obtain egg yolk antibodies with a maximum titer of more than 1:102400. The egg yolk antibodies are used in pig feed to effectively increase the feed intake and average daily weight gain of piglets, reduce the feed-to-meat ratio, and greatly improve the economic benefits of breeding.